Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Lucia Crispoltoni is active.

Publication


Featured researches published by Lucia Crispoltoni.


Neurobiology of Aging | 2014

miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer's disease

Roberto Tiribuzi; Lucia Crispoltoni; Serena Porcellati; Martina Di Lullo; Fulvio Florenzano; Matteo Pirro; Francesco Bagaglia; Toshitaka Kawarai; Mauro Zampolini; Aldo Orlacchio; Antonio Orlacchio

Alzheimers disease (AD), the most common form of dementia in elderly individuals, is characterized by neurofibrillary tangles, extracellular amyloid-β (Aβ) plaques and neuroinflammation. New evidence has shown that the lysosomal system might be a crossroad in which etiological factors in AD pathogenesis converge. This study shows that several lysosomal enzymes, including Cathepsin B, D, S, β-Galactosidase, α-Mannosidase, and β-Hexosaminidase, were less expressed in monocytes and lymphocytes from patients with a clinical diagnosis of AD dementia compared with cells from healthy controls. In vitro experiments of gain and loss of function suggest that down-regulation is a direct consequence of miR-128 up-regulation found in AD-related cells. The present study also demonstrates that miR-128 inhibition in monocytes from AD patients improves Aβ(1-42) degradation. These results could contribute to clarify the molecular mechanisms that affect the imbalanced Aβ production/clearance involved in the pathogenesis of AD.


Journal of Alzheimer's Disease | 2011

Lysosomal β-Galactosidase and β-Hexosaminidase Activities Correlate with Clinical Stages of Dementia Associated with Alzheimer's Disease and Type 2 Diabetes Mellitus

Roberto Tiribuzi; Antonio Orlacchio; Lucia Crispoltoni; Mariangela Maiotti; Mauro Zampolini; Massimiliano De Angeliz; Patrizia Mecocci; Roberta Cecchetti; Giorgio Bernardi; Alessandro Datti; Sabata Martino; Aldo Orlacchio

Multiple epidemiological studies have shown that individuals affected by type-2 diabetes mellitus (T2DM) carry a 2-to-5-fold higher risk of developing Alzheimers disease (AD) when compared to non-diabetic subjects. Thus, biochemical parameters that can be easily and routinely assessed for high-confidence evaluation of diabetic conditions leading to AD (AD-T2DM) are regarded as efficient tools aimed at early diagnosis and, in turn, timely AD treatment. In this regard, the activity of lysosomal glycohydrolases may of use, in light of the implication of these enzymes in early events that underlie AD pathology and an overt correlation, in diabetes, between altered metabolic homeostasis, abnormal glycohydrolase secretion in body fluids, and occurrence of diabetic complications. Based on marked up-regulation previously shown in a peripheral, cell-based model of AD, we selected β-Galactosidase, β-Hexosaminidase, and α-Mannosidase to discriminate T2DM from AD-T2DM subjects. A screen of 109, 114, and 116 patients with T2DM, AD and AD-T2DM, respectively, was performed by testing enzyme activities in both blood plasma and peripheral blood mononuclear cells. Compared to age-matched, healthy controls (n = 122), β-Galactosidase and β-Hexosaminidase activities markedly diverged across the three groups, whereas virtually unchanged values were observed for α-Mannosidase. In particular, plasma β-Galactosidase and β-Hexosaminidase levels were higher in patients with AD-T2DM compared to those with T2DM, suggesting different mechanisms leading to enzyme secretion. Statistical analyses based on ROC curves showed that both β-Galactosidase and β-Hexosaminidase activities, either intracellular or plasma-secreted, may be used to discriminate AD patients from controls and AD-T2DM from T2DM patients.


International Journal of Biomedical Imaging | 2011

Development of a new tool for 3d modeling for regenerative medicine

Filippo Mattoli; Roberto Tiribuzi; Francesco D'Angelo; Ilaria di Girolamo; Mattia Quattrocelli; Simona Montesano; Lucia Crispoltoni; Vasileios Oikonomou; Maria Gabriella Cusella De Angelis; Peggy Marconi; Antonio Orlacchio; Maurilio Sampaolesi; Sabata Martino; Aldo Orlacchio

The effectiveness of therapeutic treatment based on regenerative medicine for degenerative diseases (i.e., neurodegenerative or cardiac diseases) requires tools allowing the visualization and analysis of the three-dimensional (3D) distribution of target drugs within the tissue. Here, we present a new computational procedure able to overcome the limitations of visual analysis emerging by the examination of a molecular signal within images of serial tissue/organ sections by using the conventional techniques. Together with the 3D anatomical reconstitution of the tissue/organ, our framework allows the detection of signals of different origins (e.g., marked generic molecules, colorimetric, or fluorimetric substrates for enzymes; microRNA; recombinant protein). Remarkably, the application does not require the employment of specific tracking reagents for the imaging analysis. We report two different representative applications: the first shows the reconstruction of a 3D model of mouse brain with the analysis of the distribution of the β-Galactosidase, the second shows the reconstruction of a 3D mouse heart with the measurement of the cardiac volume.


Cell Biochemistry and Function | 2014

Caspase 3 activation and PARP cleavage in lymphocytes from newborn babies of diabetic mothers with unbalanced glycaemic control.

Federica Tarquini; Roberto Tiribuzi; Lucia Crispoltoni; Serena Porcellati; A. M. Del Pino; Antonio Orlacchio; G. Coata; S. Arnone; E. Torlone; Benito Cappuccini; G. C. Di Renzo

Several epidemiological studies showed that gestational diabetes mellitus is the most frequent metabolic disorder of pregnancy, the pathogenesis of which has yet to be completely clarified.


Biological Chemistry | 2016

A role for NGF and its receptors TrKA and p75NTR in the progression of COPD.

Anna Maria Stabile; Alessandra Pistilli; Lucia Crispoltoni; Claudia Montagnoli; Roberto Tiribuzi; Lucio Casali; Mario Rende

Abstract Nerve growth factor and its receptors, TrkA and p75NTR, are involved in inflammation and airways diseases, but their role in chronic obstructive pulmonary disease is still unclear and not well investigated. our data indicate the stage dependent variation of nerve growth factor and its receptors in chronic obstructive pulmonary disease progression. In fact, for the first time, this study evaluates the presence of nerve growth factor and its receptors in serum and in peripheral blood mononuclear cells of patients with different stages of chronic obstructive pulmonary disease compared to healthy subjects, non-smoker and current smoker. Serum monocyte chemoattractant protein-1, tumor necrosis factor-α, interleukin-10 and forced expiratory volume in 1 s were also analyzed. Compared to healthy subjects, chronic obstructive pulmonary disease patients presented a staging-dependent increase in serum nerve growth factor, negatively correlated to forced expiratory volume in 1 s and positively to monocyte chemoattractant Protein-1. The percentage of p75NTR+ peripheral blood mononuclear cells increased in early stages of chronic obstructive pulmonary disease (I–II), while TrKA+ peripheral blood mononuclear cells increased in late stages (III–IV). Our data demonstrate the involvement and modulation of nerve growth factor and its receptors in chronic obstructive pulmonary disease and in its staging.


Biological Chemistry | 2017

β-NGF and β-NGF receptor upregulation in blood and synovial fluid in osteoarthritis

Claudia Montagnoli; Roberto Tiribuzi; Lucia Crispoltoni; Alessandra Pistilli; Anna Maria Stabile; Francesco Manfreda; Giacomo Placella; Mario Rende; Giuliano Giorgio Cerulli

Abstract Osteoarthritis (OA) of the knee is the most common form of non-traumatic joint disease. Previous studies have shown the involvement of β-NGF and its receptors TrKA and p75NTR in OA-related pain, but their role in its pathogenesis is still unclear. The aim of our study was to investigate the amount of β-NGF and the expression levels of its receptors on cells isolated from synovial fluid and blood from OA patients who had undergone total knee arthroplasty, in order to check any possible correlation with the disease staging. Our results show a progressive stage-related increase of β-NGF and its receptors both in serum and synovial fluid. Furthermore, with respect to control subjects, OA patients show an increased amount of inflammatory monocytes along with an increased expression of β-NGF, TrKA and p75NTR. In conclusion, our study suggests a stage-related modulation of β-NGF and its receptors in the inflammatory process of OA.


Growth Factors Journal | 2015

LY294002 induces in vitro apoptosis and overexpression of p75NTR in human uterine leiomyosarcoma HTB 114 cells

Alessandra Pistilli; Mario Rende; Lucia Crispoltoni; Claudia Montagnoli; Anna Maria Stabile

Abstract Uterine leiomyosarcoma is a severe neoplasia resistant to conventional therapies. In previous studies, we have shown that human SK-UT-1 (ATCC HTB114) uterine leiomyosarcoma cell line secretes nerve growth factor (NGF) and expresses its receptors tyrosine kinase A receptor (TrKA) and low affinity nerve growth factor receptor (p75NTR). Furthermore, we have demonstrated that direct chemical inhibition or IgG neutralization of TrKA receptor induce apoptosis through p75NTR. In the present study, HTB114 cells were exposed to the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 with and without β-NGF: apoptosis, cell cycle, activation of caspase-3 and protein kinase B (AKT) and TrKA/p75NTR phenotypic expression were evaluated. According to the type of exposure, LY294002 not only induced a relevant increase in apoptosis, but also produced a novel and unexpected phenotypic modulation of the NGF receptors with a downregulation of TrKA and an upregulation of p75NTR. This latter increase enhanced HTB114 apoptosis. Our study confirms that the interference on NGF transduction is a promising therapeutical approach in uterine leiomyosarcoma.


Frontiers in Physiology | 2018

Impact of Nitric Oxide Bioavailability on the Progressive Cerebral and Peripheral Circulatory Impairments During Aging and Alzheimer's Disease

Massimo Venturelli; Anna Pedrinolla; Ilaria Boscolo Galazzo; Cristina Fonte; Nicola Smania; Stefano Tamburin; Ettore Muti; Lucia Crispoltoni; Annamaria Stabile; Alessandra Pistilli; Mario Rende; Francesca B. Pizzini; Federico Schena

Advanced aging, vascular dysfunction, and nitric oxide (NO) bioavailability are recognized risk factors for Alzheimers disease (AD). However, the contribution of AD, per se, to this putative pathophysiological mechanism is still unclear. To better answer this point, we quantified cortical perfusion with arterial spin labeling (PVC-CBF), measured ultrasound internal carotid (ICA), and femoral (FA) artery blood flow in a group of patients with similar age (~78 years) but different cognitive impairment (i.e., mild cognitive impairment MCI, mild AD-AD1, moderate AD-AD2, and severe AD-AD3) and compared them to young and healthy old (aged-matched) controls. NO-metabolites and passive leg-movement (PLM) induced hyperemia were used to assess systemic vascular function. Ninety-eight individuals were recruited for this study. PVC-CBF, ICA, and FA blood flow were markedly (range of 9–17%) and significantly (all p < 0.05) reduced across the spectrum from YG to OLD, MCI, AD1, AD2, AD3 subjects. Similarly, plasma level of nitrates and the values of PLM were significantly reduced (range of 8–26%; p < 0.05) among the six groups. Significant correlations were retrieved between plasma nitrates, PLM and PVC-CBF, CA, and FA blood flow. This integrative and comprehensive approach to vascular changes in aging and AD showed progressive changes in NO bioavailability and cortical, extracranial, and peripheral circulation in patients with AD and suggested that they are directly associated with AD and not to aging. Moreover, these results suggest that AD-related impairments of circulation are progressive and not confined to the brain. The link between cardiovascular and the central nervous systems degenerative processes in patients at different severity of AD is likely related to the depletion of NO.


International Journal of Molecular Sciences | 2017

A Comparison of Lysosomal Enzymes Expression Levels in Peripheral Blood of Mild- and Severe-Alzheimer’s Disease and MCI Patients: Implications for Regenerative Medicine Approaches

Francesco Morena; Chiara Argentati; Rosa Trotta; Lucia Crispoltoni; Anna Maria Stabile; Alessandra Pistilli; Angela di Baldassarre; Riccardo Calafiore; Pia Montanucci; Giuseppe Basta; Anna Pedrinolla; Nicola Smania; Massimo Venturelli; Federico Schena; Fabio Naro; Carla Emiliani; Mario Rende; Sabata Martino

The association of lysosomal dysfunction and neurodegeneration has been documented in several neurodegenerative diseases, including Alzheimer’s Disease (AD). Herein, we investigate the association of lysosomal enzymes with AD at different stages of progression of the disease (mild and severe) or with mild cognitive impairment (MCI). We conducted a screening of two classes of lysosomal enzymes: glycohydrolases (β-Hexosaminidase, β-Galctosidase, β-Galactosylcerebrosidase, β-Glucuronidase) and proteases (Cathepsins S, D, B, L) in peripheral blood samples (blood plasma and PBMCs) from mild AD, severe AD, MCI and healthy control subjects. We confirmed the lysosomal dysfunction in severe AD patients and added new findings enhancing the association of abnormal levels of specific lysosomal enzymes with the mild AD or severe AD, and highlighting the difference of AD from MCI. Herein, we showed for the first time the specific alteration of β-Galctosidase (Gal), β-Galactosylcerebrosidase (GALC) in MCI patients. It is notable that in above peripheral biological samples the lysosomes are more sensitive to AD cellular metabolic alteration when compared to levels of Aβ-peptide or Tau proteins, similar in both AD groups analyzed. Collectively, our findings support the role of lysosomal enzymes as potential peripheral molecules that vary with the progression of AD, and make them useful for monitoring regenerative medicine approaches for AD.


Alzheimers & Dementia | 2013

MiR128 up-regulation correlates with impaired beta-amyloid 42 degradation in monocytes of patients with sporadic Alzheimer's disease

Roberto Tiribuzi; Lucia Crispoltoni; Serena Porcellati; Marzia Mearini; Martina Di Lullo; F. Florenzano; Matteo Pirro; Francesco Bagaglia; Carlo Alberto Palmerini; Marialuisa Miele; Toshitaka Kawarai; Mauro Zampolini; Aldo Orlacchio; Antonio Orlacchio

Niemann-Pick type C1 knockout mice, which accumulate cholesterol in late endosomes/lysosomes, we hypothesize that the impaired cholesterol homeostasis described in AD may play a role. The aim of this work was to examine how changes in cholesterol regulate autophagy in AD. Methods: For this purpose, we used APP/PS1 transgenic mice that overexpress the sterol regulatory element binding protein 2 (APP/PS1/SREBP2) and display increased cholesterol levels (total and mitochondrial) associated with depleted mitochondrial GSH (mGSH). Results: High cholesterol was also observed in lysosomes. Western blot analysis showed increased levels of LC3-I/-II. Enhanced autophagosome formation by overexpression of SREBP-2 was further confirmed by dansylcadaverine. The expression of different autophagy -related genes was unchanged in triple-transgenic mice. Additionally, we found high levels of Lamp-2 associated with increased cathepsin D maturation, however the activity of the enzyme remained unaltered; therefore, the rise in cathepsin D levels induced by cholesterol may be more likely a compensatory response to dysfunctional lysosomes. Cholesterol enrichment of neuroblastoma cell SHYSY-5Y, using U18666A or cholesterolmethyl-b-cyclodextrin complex, stimulated the autophagy triggered by serum starvation, rapamycin or a mitochondrial uncoupler. However, the addition of chloroquine did not modify LC3-II abundance in cholesterol-enriched cells indicating that the increase in autophagosomes reflects impaired fusion with lysosomes rather than increased autophagic flux. Autophagy processes in SHYSY-5Y were also initiated by amyloid b (A b) incubation with increased Beclin-1 expression and LC3 lipidation. Treatment with 3-hydroxy-4-pentenoate (HP), which selectively depletes mGSH, enhanced the presence of LC3positive structures that co-localize with the mitochondrial marker cytochrome c after A b exposure. Similar mitophagy was observed when HP-treated cells were delivered with drugs that evoke ROS production. Conclusions: Thus, according to these data we propose a model in which cholesterol play a dual role. High cholesterol levels would exacerbate A b -induced autophagy/mitophagy by depleting mitochondrial GSH content and promoting mitochondrial ROS, and in turn, autophagolysosome maturation would be affected by cholesterol-mediated lysosomal dysfunction.

Collaboration


Dive into the Lucia Crispoltoni's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge